Navigation Links
Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:10/2/2009

demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway, leaving healthy normal cells intact. At least two thirds of carcinomas and more than 90% of metastatic disease has Ras involvement.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the SPA agreement on a Phase 3 combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-refractory head and neck cancers, the planned timing and implementation of the Phase 3 trial, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. sec
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Genomics and Proteomics Analytical Instruments Market ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the ... is the study of the structure and functions of ... and bioinformatics tools and technology. Genomics involves the mapping ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... 1, 2011 Tengion, Inc. (Nasdaq: TNGN ), ... entered into definitive agreements with certain investors in connection with ... Securities Act of 1933, as amended.  Medtronic (NYSE: ... the financing and, as part of its investment, secured a ...
... Wash., March 1, 2011 Iverson Genetic Diagnostics, Inc. announced ... dverse Event R eduction f or A ... itiation) was initiated at WellStar Health System in Marietta and ... genetic testing to determine a personalized warfarin dose for individual ...
... gold particles are currently intensively investigated for possible ... and molecular electronics. The particles are prepared in ... gold cores can be stabilised with various organic ... using organothiolate ligands that have a strong chemical ...
Cached Biology Technology:Tengion Announces Pricing of $31.4 Million Private Placement 2Tengion Announces Pricing of $31.4 Million Private Placement 3WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 4Fingerprints of a gold cluster revealed 2
(Date:7/23/2014)... DIEGO , July 24, 2014 Pfenex Inc. ... public offering of 8,333,333 shares of its common stock at ... addition, Pfenex has granted the underwriters a 30-day option to ... the initial public offering price. The shares are expected to ... under the symbol "PFNX". William Blair ...
(Date:7/23/2014)... Children who have been abused or neglected early ... emotional and physical health problems. In a new ... way genes are activated, which has implications for ... a particular child,s individual characteristics and genetics interacted ... understand how health problems emerge. In the new ...
(Date:7/23/2014)... In Aesop,s fable about the crow and the pitcher, a ... he tries to drink from it, he finds the water ... over the pitcher, the bird drops pebbles into it ... enough for him to drink his fill. , Highlighting the ... often be more effective than brute force. It also characterizes ...
Breaking Biology News(10 mins):Pfenex Inc. Announces Pricing Of Initial Public Offering 2Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4
... EAST LANSING, Mich. A repellant for sea lampreys could ... destructive invasive species in the Great Lakes, says a Michigan ... cues have on lampreys. When scents from dead sea lampreys ... efforts to escape are dramatic. In the past, these reactions ...
... used to the fact that most new-born foals suffer from ... including supplementing the mothers, diets with -carotene, which is known ... However, Juliane Kuhl in the group of Christine Aurich at ... this food supplement has no real effect on the incidence ...
... led by Professor Malcolm McConville from the Bio21 Institute, University ... used for many infectious parasites and bacteria. The technique has ... down to the particular atoms it uses as a food ... field because the more we know about these dangerous pathogens ...
Cached Biology News:Sea lampreys fear the smell of death 2No treatment is the best treatment -- diarrhea in young foals 2
... The Polymerase gene from Thermus aquaticus ... in E. coli, then highly purified ... is used in the amplification and ... The quality of the Taq DNA ...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 5,000 units polymerase, ...
Rabbit polyclonal to hnRNP-U...
... is an antibody-mediated hot-start DNA ... and real-time PCR applications. The ... concentration of 5 units per ... polymerase, 1.25 ml 10x PCR ...
Biology Products: